Answers are grounded in this paper and cite their sources.
The spiroindolone cipargamin, a new antimalarial compound that inhibits Plasmodium ATP4, is currently in clinical development. This study aimed to characterize the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum .
No takes yet. Share an insight, caveat, or question.
McCarthy et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: